1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts BioNTech's Price Target to $284 from $294, Keeps Equalweight Rating

01/18/2022 | 12:20pm EDT


© MT Newswires 2022
All news about BIONTECH SE
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
MT
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/19European ADRs Move Higher in Thursday Trading
MT
05/17Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
MT
05/17UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating
MT
05/17Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
MT
05/17Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
MT
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/17PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech..
DJ
05/16European ADRs Move Higher in Monday Trading
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 934 M 17 929 M 17 929 M
Net income 2022 9 078 M 9 612 M 9 612 M
Net cash 2022 15 700 M 16 622 M 16 622 M
P/E ratio 2022 4,49x
Yield 2022 -
Capitalization 38 531 M 40 796 M 40 796 M
EV / Sales 2022 1,35x
EV / Sales 2023 1,23x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 158,55 €
Average target price 225,92 €
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-34.88%40 796
GILEAD SCIENCES, INC.-12.86%79 298
REGENERON PHARMACEUTICALS, INC.4.06%71 026
VERTEX PHARMACEUTICALS16.33%64 540
WUXI APPTEC CO., LTD.-19.12%41 409
GENMAB A/S-19.16%19 651